Affidea introduces the Roczen platform from Reset Health for
the management of obesity and type 2 diabetes, offering
personalised care, GLP-1 medications, and improved health outcomes
for patients
THE
HAGUE, Netherlands, Nov. 4, 2024
/PRNewswire/ -- Affidea, the leading pan-European provider of
community-based polyclinics, advanced diagnostics and specialist
services, is excited to announce a strategic long-term
collaboration with Reset Health for the implementation of Roczen, a
doctor-led, digital care model designed to treat and manage obesity
and type 2 diabetes.
This new solution will be rolled out across Affidea markets in
the coming period, offering patients access to a clinically proven,
data-driven care pathway that combines advanced analytics with
evidence-based interventions to improve health outcomes in managing
obesity and its related chronic conditions.
Designed as a fully digital, doctor-led service, the platform
addresses obesity and type 2 diabetes by combining sustainable
lifestyle changes with new innovative medical interventions.
Key features include:
- Comprehensive pathway to support patients
- Continuous tracking of vital health metrics to provide timely
interventions.
- Personalised treatment plans based on real-time patient data
and health needs.
- Direct communication between patients and healthcare providers
for better management and ongoing support.
- Support offered on sustainable behaviour changes, including
dietary modifications, physical activity, and mental health.
- Access to GLP-1 medications for qualifying patients, supporting
comprehensive chronic disease management.
Affidea's collaboration with Reset Health and the introduction
of the Roczen platform marks a significant step in expanding
Affidea's clinical services to meet the growing demand for
effective weight and diabetes management solutions. This
partnership aligns with Affidea's mission to deliver innovative,
patient-focused care pathways, ensuring patients have access to the
latest therapeutic options, including GLP-1 medications. By
integrating digital therapeutics with professional healthcare
support, Affidea's centres will offer personalised, accessible, and
affordable care, helping patients manage obesity and type 2
diabetes more effectively while reducing the risk of long-term
complications.
Dr Charles Niehaus, Executive
Director for Affidea Group, commented: "At Affidea, we are
dedicated to providing the highest quality of care for our
patients, tailored for their individual needs. The Roczen platform
we are now implementing for a comprehensive pathway allows us to
offer a clinically validated approach to weight management and
diabetes care that directly addresses two of the most pressing
health issues of our time. By offering personalised, evidence-based
interventions, we are empowering our patients to take control of
their health and improve their quality of life."
Dr David Wong, Chairman at
Reset Health, said: "We are excited to partner with
Affidea and together be at the forefront of delivering
high-quality, clinically-proven weight management and diabetes care
across Europe. By providing access
to Roczen, our doctor-led care model, we will support people living
with obesity and type 2 diabetes to have individualised care that
is tailored to their needs. By improving patient experience and
engagement, we seek to deliver better outcomes."
Key Facts on Obesity and its Impact, according to
WHO:
- Nearly 60% of adults in Europe
are overweight, and 23% are classified as obese. One in three
school-aged children is also classified as obese.
- 1.2 million deaths annually in the European region are
attributable to overweight and obesity.
- By 2030, projections from the World Health Organization (WHO)
suggest that obesity rates in Europe could rise by 10-15%, with as many as
30% of adults becoming obese.
- Obesity is strongly linked to type 2 diabetes, with 80-90% of
individuals with type 2 diabetes being overweight or obese.
- Around 70% of individuals with obstructive sleep apnea are
obese.
- Obesity increases the risk of osteoarthritis in the knee by
four times.
- There is a 33% increased risk of Alzheimer's disease and a 64%
increased risk of any dementia for obese patients.
- There is a strong correlation between obesity and mental health
issues, including depression, anxiety, and eating disorders.
About Affidea
Affidea (www.affidea.com) is a leading pan-European provider of
community-based polyclinics, advanced diagnostics and specialist
services. Founded in 1991, the company operates 380 centres across
15 countries, providing high-quality medical services to nearly 14
million patients every year. Due to its track record for patient
safety, the company has become the most awarded diagnostic imaging
provider in Europe by the European
Society of Radiology, as over 90% of its centres are recognised on
the Eurosafe Wall of Stars by the European Society of
Radiology. Affidea is majority-owned by Groupe Bruxelles
Lambert (GBL), a leading investment holding company, focused on
long-term value-creation with a stable and supportive family
shareholder base.
About Reset Health
Reset Health (www.resethealth.clinic) is a digital health
company delivering scalable clinical solutions and is a leader
in personalised lifestyle interventions. Reset's digital
platform and care model, Roczen (www.roczen.com), is used in
conjunction with new anti-obesity medications, GLP-1s and GIPs, to
enhance health outcomes of patients with obesity and associated
co-morbidities. Reset Health is regulated by the Care Quality
Commission and recommended by the National Institute of Clinical
Excellence (NICE). Reset Health is the provider of obesity and Type
2 Diabetes care across the UK and Malaysia where it delivers its programmes and
platform to over 500,000 people, working with governments,
employers, insurers, private providers and health systems.
Logo:
https://mma.prnewswire.com/media/942742/4502210/Affidea_Group_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/affidea-group-partners-with-reset-health-to-launch-clinically-led-digital-weight-loss-and-diabetes-management-solution-across-its-network-302295297.html
